Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,717.00-0.11%ETH$2,283.62+1.03%GOLD$3,910.80+0.31%OIL$99.52-4.42%
Smart Investors Daily
SID Premium
CA

NASDAQ · CADL

Candel Therapeutics, Inc.

Healthcare · Biotechnology

$8.33

Down-$0.32 (-3.70%)

Updated Nov 2, 2026, 12:23 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
355.76M
P/E ratio
-30.96
Dividend yield
0.00%
52-week range
$4.44 – $14.00
Volume
779.93K
Avg. volume
778.62K

Price performance · CADL

CADL price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

CADL closed at $8.33 after 20 trading sessions, down 18.57% for the selected period.

Last close
$8.33
Period change
-18.57%
Period low
$7.79
Period high
$10.23
Daily close
View OHLC price history
CADL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$8.56$8.61$8.16$8.33779.93K
Oct 29, 2026$8.72$8.93$8.5526$8.65740.96K
Oct 28, 2026$8.13$8.69$8.13$8.67663.86K
Oct 27, 2026$7.78$8.37$7.741$8.25928.46K
Oct 26, 2026$8.44$8.44$7.70$7.79849.3K
Oct 23, 2026$8.33$8.33$7.905$8.031.18M
Oct 22, 2026$8.45$8.79$8.255$8.38762.58K
Oct 21, 2026$8.65$8.82$8.35$8.371.1M
Oct 20, 2026$8.17$8.84$8.125$8.641.13M
Oct 19, 2026$8.37$8.4994$7.96$8.211.28M
Oct 16, 2026$8.92$8.92$8.125$8.191.51M
Oct 15, 2026$9.01$9.0999$8.79$8.91989.34K
Oct 14, 2026$9.06$9.43$9.03$9.07989.44K
Oct 13, 2026$9.78$9.845$9.22$9.271.13M
Oct 12, 2026$10.00$10.18$9.71$9.78744.63K
Oct 9, 2026$9.69$9.95$9.59$9.94718.37K
Oct 8, 2026$9.70$9.755$9.45$9.66888.5K
Oct 7, 2026$9.75$9.945$9.60$9.82714.95K
Oct 6, 2026$10.32$10.40$9.85$9.87977.77K
Oct 5, 2026$10.27$10.45$9.94$10.23980.89K

Latest CADL news

The latest Smart Investors Daily articles mentioning CADL.

Stock researchCompany · Overview

CADL research

Overview

Company profile and research snapshot.

Company profile

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$15.00
Implied upside
—
Analysts
14
CADL recent ratings
DateFirmRatingTarget
Oct 22, 2026JefferiesBuy—
Sep 21, 2026B of A SecuritiesBuy—
Aug 14, 2026B of A SecuritiesNeutral—
Aug 13, 2026HC Wainwright & Co.Buy—
Jul 13, 2026StifelBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Candel Therapeutics to Present at November Investor Conferences

NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in November 2026. Key

Yahoo · Oct 22, 2026

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

Seasoned legal and compliance executive brings global product launch, strategic transaction and international operational experience as Candel prepares for its planned Biologics License Application (BLA) submission and potential commercialization NEEDHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with

Yahoo · Oct 2, 2026

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By